Dual-ligand peptide/UiO-66-NH2@AYG fluorescent probe achieves ultrasensitive CA15-3 detection for early breast cancer screening
Background
Early and accurate detection of breast cancer is crucial for improving patient outcomes, yet current diagnostic methods often lack the sensitivity or cost-effectiveness required for widespread screening. Carbohydrate antigen 15-3 (CA15-3) serves as a key biomarker for both early diagnosis and monitoring therapeutic responses in breast cancer patients. However, existing detection platforms may not offer the necessary combination of high sensitivity, specificity, and affordability for primary healthcare settings, leaving a gap for more advanced, accessible diagnostic tools.
Study Design
Researchers constructed an ultrasensitive fluorescent probe utilizing a dual-ligand peptide/UiO-66-NH2@AYG composite material for CA15-3 detection. The probe incorporates two distinct peptides, GTTFSNYW and MHYLEYPF, designed to target different CA15-3 epitopes, thereby enhancing binding affinity and specificity. These peptides were immobilized onto UiO-66-NH2, a metal-organic framework known for its high surface area, which also efficiently loaded the fluorescent reporter Acridine Yellow G (AYG). The probe's performance was evaluated using fluorescence detection in a linear range, spiked mouse serum samples, and clinical serum samples from 10 cancer patients, with results compared against ELISA.
Results
The developed dual-ligand peptide/UiO-66-NH2@AYG probe demonstrated exceptional analytical performance for CA15-3 detection. It exhibited a linear detection range from 0.05-1.5 pg/mL with a high correlation coefficient of R2 = 0.9981. The probe achieved an ultralow detection limit of 0.004147 pg/mL, significantly enhancing sensitivity. Practical validation in spiked mouse serum samples showed excellent recovery rates ranging from 91.57-103.7%, indicating robust performance in biological matrices. Furthermore, clinical testing with serum samples from 10 cancer patients revealed a strong positive correlation with established ELISA results, with a correlation coefficient of r = 0.9944 and a high statistical significance of P < 0.001. This confirms the probe's accuracy and reliability in a clinical context.
The probe achieved an ultralow detection limit of 0.004147 pg/mL, demonstrating superior sensitivity for CA15-3 detection.
Key Findings
- Dual-ligand peptide/UiO-66-NH2@AYG probe detects CA15-3 with high sensitivity.
- Achieved an ultralow detection limit of 0.004147 pg/mL for CA15-3.
- Demonstrated a linear detection range of 0.05-1.5 pg/mL (R2 = 0.9981).
- Showed 91.57-103.7% recovery rates in spiked mouse serum samples.
- Strong correlation with
ELISAresults in 10 cancer patients (r = 0.9944, P < 0.001).
Why It Matters
This novel fluorescent probe represents a significant step towards enabling highly sensitive and cost-effective early breast cancer screening in primary healthcare. The dual-ligand peptide strategy, targeting multiple CA15-3 epitopes, offers enhanced specificity and affinity, which could lead to fewer false positives and earlier disease detection. For clinicians and biohackers, this technology suggests a future where routine cancer biomarker screening could be more accessible and affordable, potentially shifting early diagnostic capabilities to point-of-care settings. While currently a research platform, its robust performance in clinical samples indicates strong potential for translation into a usable diagnostic protocol, though further large-scale clinical validation is essential before widespread adoption.
ca15-3
breast-cancer
fluorescent-probe
biomarker-detection
peptides
diagnostic